MolPAGE (Molecular Phenotyping to Accelerate Genomic Epidemiology) is an EU consortium with almost twenty collaborating universities and companies throughout Europe. One of the aims of MolPAGE is to find early-onset biomarkers for type 2 diabetes (T2DM) and cardiovascular diseases(CVD). Novo Nordisk in Denmark and Imperial College in London are the two partners cooperating closely within the area of metabonomics. Novo Nordisk commitment in MolPAGE also covers transcriptomics.
Authors: K. Magnus Åberg, Mark Jairaj, Henrik Toft Pedersen, Dorrit Baunsgaard
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License